The global market for contract research organization services is projected to grow strongly through 2031, with the industry expected to reach USD 140.32 billion. The outlook reflects rising demand from pharmaceutical and biopharmaceutical companies as they continue to outsource more research, development and trial-related work to specialized service providers.
The report indicates that pharmaceutical and biopharmaceutical companies accounted for the largest share of the market in 2025. Early-stage development services also represented a major portion of demand, highlighting how drugmakers are increasingly relying on external partners at the front end of the pipeline to improve speed, flexibility and access to technical expertise.
A key driver behind the expansion is the growing complexity of advanced therapies and precision medicine programs. These areas often require highly specialized development capabilities, data handling and trial design support, making outsourcing a more practical option for many sponsors seeking to manage costs and timelines while navigating more targeted treatment approaches.
Regionally, North America remained the leading market, supported by established clinical trial infrastructure and broader use of digital health-related capabilities. The overall trend points to continued momentum for CRO providers as drug developers look for scalable support across research and clinical development in an increasingly specialized market.
